

2

Docket No. GJE-88
Serial No. 10/070,568In the Claims:

1 (cancel).

2 (currently amended). The insulin analogue, according to claim 18, wherein the Tyr at the 26th amino-acid position of the B chain of human insulin (~~Tyr~~) is substituted by Ala.

3 (cancel).

4 (currently amended). The insulin analogue, according to claim 18, wherein the Tyr at the 16th amino-acid position of the B chain of human insulin (~~Tyr~~) is substituted by Ala.

5 (cancel).

6 (currently amended). A method for treating an individual having an insulin deficiency wherein said method comprises administering to the individual an insulin analogue wherein the Tyr at the 16th or 26th amino-acid position of the B chain of human insulin (~~Tyr~~) is substituted by Ala, and said analogue has a deletion at either one or both of Phe at position 1, B1, or Thr at position 30, B30, of the B-chain of human insulin.

7 (cancel).

8 (previously presented). The method, according to claim 6, wherein, at the 26th amino acid, the analogue is substituted by Ala.

9 (previously presented). The method, according to claim 8, wherein said analogue has a deletion of B30.

3

Docket No. GJE-88
Serial No. 10/070,568

10 (previously presented). The method, according to claim 6, wherein at the 16th amino acid, the analogue is substituted by Ala.

11 (previously presented). The method, according to claim 10, wherein said analogue has a deletion at B30.

12 (currently amended). A pharmaceutical composition comprising an insulin analogue ~~wherein the 16th or 26th amino acid of the B chain of human insulin (Tyr) is substituted by Ala,~~ wherein the Tyr at the 16th or 26th position of the B chain of human insulin is substituted by Ala, and said analogue has a deletion at either one or both of Phe at position 1, B1, or Thr at position 30, B30, of the B-chain of human insulin wherein said composition further comprises a pharmaceutical carrier.

13 (cancel).

14 (previously presented). The pharmaceutical composition, according to claim 12, wherein at the 26th amino acid, the analogue is substituted by Ala.

15 (previously presented). The pharmaceutical composition, according to claim 14, wherein said analogue has a deletion of B30.

16 (previously presented). The pharmaceutical composition, according to claim 12, wherein at the 16th amino acid, the analogue is substituted by Ala.

17 (previously presented). The pharmaceutical composition, according to claim 16, wherein said analogue has a deletion at B30.

18 (new). An insulin analogue wherein the Tyr at the 16th or 26th position of the B-chain of human insulin is substituted by Ala, and which also comprises a deletion of Phe at position 1, B1, of the B-chain of human insulin.

19 (new). A method for treating an individual having an insulin deficiency wherein said method comprises administering to the individual an insulin analogue wherein the Tyr at the 16th position of the B-chain of human insulin is substituted by Ala, and wherein there is no deletion of Phe at position 1, B1, or Thr at position 30, B30, of the B-chain of human insulin.

20 (new). The method, according to claim 19, wherein at the 16th amino acid, the analogue is substituted by Ala.

21 (new). A pharmaceutical composition comprising an insulin analogue wherein the Tyr at the 16th position of the B-chain of human insulin is substituted by Ala; wherein there is no deletion of Phe at position 1, B1, or Thr at position 30, B30, of the B-chain of human insulin; and wherein said composition further comprises a pharmaceutical carrier.